SPRY3 and breast cancer: Immunoblotting of logarithmically growing cells revealed that in contrast to breast cancer-derived cell lines, cells originated from osteosarcoma express prominent levels of Spry3 exceeding the ones observed in the brain cancer cell lines (Figure 1).